中华结核和呼吸杂志
中華結覈和呼吸雜誌
중화결핵화호흡잡지
Chinese Journal of Tuberculosis and Respiratory Diseases
2010年
5期
359-362
,共4页
段鸿飞%土井教生%李琦%马屿%陈效友%傅瑜
段鴻飛%土井教生%李琦%馬嶼%陳效友%傅瑜
단홍비%토정교생%리기%마서%진효우%부유
分枝杆菌,鸟复合%微生物敏感性试验
分枝桿菌,鳥複閤%微生物敏感性試驗
분지간균,조복합%미생물민감성시험
Mycobacterium avium complex%Microbial sensitivity tests
目的 通过比较3种新型喹诺酮类药物(西他沙星、加替沙星和莫西沙星)与其他13种抗感染药物对鸟分枝杆菌复合群(MAC)分离株的体外活性,初步探讨喹诺酮类药物用于治疗MAC疾病的可能性.方法 琼脂梯度稀释法测定上述16种抗感染药物对MAC分离株的最低抑菌浓度(MIC),比较其能抑制90%菌株生长的MIC(MIC90).结果 与胞内分枝杆菌相比,鸟分枝杆菌菌株的MIC范围分布更广,且MIC90多高于胞内分枝杆菌.4种大环内酯类药物中,克拉霉素对鸟分枝杆菌和胞内分枝杆菌的MIC90最低,分别为32和16 mg/L;4种利福霉素类化合物中利福拉齐对鸟分枝杆菌和胞内分枝杆菌的MIC90最低,分别为0.5和0.25 mg/L;5种喹诺酮类药物中西他沙星对鸟分枝杆菌和胞内分枝杆菌的MIC90最低,均为4 mg/L,加替沙星和莫西沙星均为8 mg/L.2株克拉霉素敏感株(MIC=0.5 mg/L)对其他抗感染药物均接近或达到MIC范围的下限,3株克拉霉素不敏感株(MIC=64 mg/L)对除喹诺酮类以外的抗感染药物均接近MIC范围的上限.结论 利福拉齐、西他沙星、加替沙星和莫西沙星对MAC分离株具有较强的体外活性.
目的 通過比較3種新型喹諾酮類藥物(西他沙星、加替沙星和莫西沙星)與其他13種抗感染藥物對鳥分枝桿菌複閤群(MAC)分離株的體外活性,初步探討喹諾酮類藥物用于治療MAC疾病的可能性.方法 瓊脂梯度稀釋法測定上述16種抗感染藥物對MAC分離株的最低抑菌濃度(MIC),比較其能抑製90%菌株生長的MIC(MIC90).結果 與胞內分枝桿菌相比,鳥分枝桿菌菌株的MIC範圍分佈更廣,且MIC90多高于胞內分枝桿菌.4種大環內酯類藥物中,剋拉黴素對鳥分枝桿菌和胞內分枝桿菌的MIC90最低,分彆為32和16 mg/L;4種利福黴素類化閤物中利福拉齊對鳥分枝桿菌和胞內分枝桿菌的MIC90最低,分彆為0.5和0.25 mg/L;5種喹諾酮類藥物中西他沙星對鳥分枝桿菌和胞內分枝桿菌的MIC90最低,均為4 mg/L,加替沙星和莫西沙星均為8 mg/L.2株剋拉黴素敏感株(MIC=0.5 mg/L)對其他抗感染藥物均接近或達到MIC範圍的下限,3株剋拉黴素不敏感株(MIC=64 mg/L)對除喹諾酮類以外的抗感染藥物均接近MIC範圍的上限.結論 利福拉齊、西他沙星、加替沙星和莫西沙星對MAC分離株具有較彊的體外活性.
목적 통과비교3충신형규낙동류약물(서타사성、가체사성화막서사성)여기타13충항감염약물대조분지간균복합군(MAC)분리주적체외활성,초보탐토규낙동류약물용우치료MAC질병적가능성.방법 경지제도희석법측정상술16충항감염약물대MAC분리주적최저억균농도(MIC),비교기능억제90%균주생장적MIC(MIC90).결과 여포내분지간균상비,조분지간균균주적MIC범위분포경엄,차MIC90다고우포내분지간균.4충대배내지류약물중,극랍매소대조분지간균화포내분지간균적MIC90최저,분별위32화16 mg/L;4충리복매소류화합물중리복랍제대조분지간균화포내분지간균적MIC90최저,분별위0.5화0.25 mg/L;5충규낙동류약물중서타사성대조분지간균화포내분지간균적MIC90최저,균위4 mg/L,가체사성화막서사성균위8 mg/L.2주극랍매소민감주(MIC=0.5 mg/L)대기타항감염약물균접근혹체도MIC범위적하한,3주극랍매소불민감주(MIC=64 mg/L)대제규낙동류이외적항감염약물균접근MIC범위적상한.결론 리복랍제、서타사성、가체사성화막서사성대MAC분리주구유교강적체외활성.
Objective To compare the in vitro activities of 13 anti-infective agents and 3 new quinolones (sitafloxacin, gatifloxacin and moxifloxacin ) against Mycobacterium avium complex (MAC)isolates ,and therefore to explore the possibility of using these quinolones to treat MAC diseases. Methods The minimal inhibitory concentration (MIC) of the above 16 anti-infective agents, including sitafloxacin,gatifloxacin and moxifloxacin against MAC isolates was determined by using agar dilution methods, and then the MIC90s of the different anti-infective agents were compared. Results The MICs of M. avium isolates showed a wider range and was less sensitive to most of the anti-infective agents as compared with M.intracellulare isolates. The MIC90s of clarithromycin against M. avium and M. intracellulare isolates were 32mg/L and 16 mg/L, respectively, which were the lowest among 4 macrolide compounds. The MIC90 of rifalazil were 0.5 mg/L and 0. 25 mg/L, respectively, which were the lowest among 4 rifamycin compounds.The MIC90 of sitafloxacin against M. avium and M. intracellulare isolates were both 4 mg/L, which were the lowest among 5 quinolones. For gatifloxacin and moxifloxacin, the MIC9o against M. avium and M.intracellulare isolates were both 8 mg/L Two clarithromycin-sensitive strains(MIC = 0.5 mg/L)showed a similar MIC of the lower limit for other compounds. Three clarithromycin-insensitive strains(MIC = 64 mg/L) showed a similar MIC of the upper limit for other compounds except quinolones. Conclusion Rifalazil,sitafloxacin, gatifloxacin and moxifloxacin showed acceptable in vitro activities against MAC isolates.